Psychiatric Quarterly

, Volume 84, Issue 1, pp 125–135 | Cite as

Quality of Life and Adverse Effects of Olanzapine Versus Risperidone Therapy in Patients with Schizophrenia

  • Katarina Melo Chaves
  • Antoni Serrano-Blanco
  • Susana Barbosa Ribeiro
  • Luiz Alberto Lira Soares
  • Gerlane Coelho Bernardo Guerra
  • Maria do Socorro Costa Feitosa Alves
  • Raimundo Fernandes de Araújo Júnior
  • Vanessa de Paula Soares Rachetti
  • Antônio Filgueira Júnior
  • Aurigena Antunes de Araújo
Original Paper

Abstract

This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr. João Machado, Natal, Rio Grande do Norte, Brazil. Socioeconomic, sociodemographic, and clinical variables were compared. The QoL Scale validated for Brazil (QLS-BR) was used to evaluate QoL, and adverse effects were assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Data were analyzed using the χ2 test and Student’s t test, with a significance level of 5 %. Patients in both drug groups showed severe impairment in the occupational domain of the QLS-BR. Global QLS-BR scores indicated impairment among risperidone users and severe impairment among olanzapine users. The most significant side effects were associated with risperidone, including asthenia/lassitude/fatigue, somnolence/sedation, paresthesia, change in visual accommodation, increased salivation, diarrhea, orthostatic posture, palpitations/tachycardia, erythema, photosensitivity, weight loss, galactorrhea, decreased sexual desire, erectile/orgasmic dysfunction, vaginal dryness, headache, and physical dependence. QoL was impaired in patients using olanzapine and in those using risperidone. Risperidone use was associated with psychic, neurological, and autonomous adverse effects and other side effects.

Keywords

Schizophrenia Atypical antipsychotic Quality of life 

References

  1. 1.
    Philip S: Antipsychotic drugs, dopamine receptors, and schizophrenia. Clinical Neuroscience Research 1(1–2):53–60, 2001Google Scholar
  2. 2.
    Abi-Dargham A, Laruelle M: Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. European Psychiatry 20(1):15–27, 2005PubMedCrossRefGoogle Scholar
  3. 3.
    Michalopoulou PG, Shergill SS, Kapur S: New and old antipsychotics: What ‘effectiveness’ trials tell us. Psychiatry 7(11):443–446, 2008CrossRefGoogle Scholar
  4. 4.
    Kao YC, Liu YP, Chou MK, Cheng TH: Subjective quality of life in patients with chronic schizophrenia: Relationships between psychosocial and clinical characteristics. Comprehensive Psychiatry 52(2):171–180, 2011PubMedCrossRefGoogle Scholar
  5. 5.
    Saarni SI, Pirkola S: Quality of life of psychiatric patients. Duodecim; laaketieteellinen aikakauskirja 126(19):2265–2273, 2010PubMedGoogle Scholar
  6. 6.
    Galuppi A, Turola MC, Nanni MG, Mazzoni P, Grassi L: Schizophrenia and quality of life: How important are symptoms and functioning? International Journal of Mental Health Systems 4:31, 2010PubMedCrossRefGoogle Scholar
  7. 7.
    Heinrichs DW, Hanlon TE, Carpenter WT: The quality of life scale—an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10(3):388–398, 1984PubMedCrossRefGoogle Scholar
  8. 8.
    Ueoka Y, Tomotake M, Tanaka T, Kaneda Y, Taniguchi K, Nakataki M, et al.: Quality of life and cognitive dysfunction in people with schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 35(1):53–59, 2011Google Scholar
  9. 9.
    Song YY, Kim KR, Park JY, Lee SY, Kang JI, Lee E, et al.: Associated factors of quality of life in first-episode schizophrenia patients. Psychiatry Investigation 8(3):201–206, 2011PubMedCrossRefGoogle Scholar
  10. 10.
    Cardoso CS, Bandeira M, Caiaffa WT, Fonseca JOP: Escala de qualidade de vida para pacientes com esquizofrenia QLS-BR: Adaptação transcultural para o Brasil. Jornal Brasileiro de Psiquiatria 51(1):31–38, 2002Google Scholar
  11. 11.
    Brasil MdSd: Aprova o componente especializado da assistência farmacêutica. Diario Oficial Uniao, p. 725, 2009Google Scholar
  12. 12.
    Manual Diagnóstico e Estatístico de Transtornos Mentais—DSM-IV-TR-TM: ArtMed Porto Alegre, 2003Google Scholar
  13. 13.
    Brasil Mdsd: Protocolo clínico e diretrizes terapêuticas—esquizofrenia refratária. In: CONASS (Ed) Brasília, 2002Google Scholar
  14. 14.
    Human D: Declaration of Helsinki. Lancet 357(9251):236, 2001PubMedCrossRefGoogle Scholar
  15. 15.
    Garcia-Navarro A, Gonzalez-Puga C, Escames G, Lopez LC, Lopez A, Lopez-Cantarero M, et al.: Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. Journal of Pineal Research 43(2):195–205, 2007PubMedCrossRefGoogle Scholar
  16. 16.
    Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 334:1–100, 1987PubMedCrossRefGoogle Scholar
  17. 17.
    Carpiniello B, Mellino G, Pintore S, Puddu L, Pinna F: Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study. Clinica Terapeutica 162(4):331–341, 2011PubMedGoogle Scholar
  18. 18.
    Cianchetti C, Ledda MG: Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison. Psychiatric Research 189(3):349–356, 2011CrossRefGoogle Scholar
  19. 19.
    Foussias G, Remington G: Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making. Canadian Journal Of Psychiatry Revue Canadienne de Psychiatrie 55(3):117–125, 2010Google Scholar
  20. 20.
    Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, et al.: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (CAMP). American Journal of Psychiatry 168(9):947–956, 2011PubMedCrossRefGoogle Scholar
  21. 21.
    Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y: Quality of life outcomes of risperidone olanzapine and typical antipsychotics among schizophrenia patients treated in routine clinical practice—a naturalistic comparative study. Journal of Clinical Psychopharmacology 24(6):582–591, 2004PubMedCrossRefGoogle Scholar
  22. 22.
    Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D: The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. Journal of Clinical Psychiatry 67(9):1397–1403, 2006Google Scholar
  23. 23.
    Leão A, Barros S: As representações sociais dos profissionais de saúde mental acerca do modelo de atenção e as possibilidades de inclusão social. Saúde e Sociedade 17:95–106, 2008CrossRefGoogle Scholar
  24. 24.
    Kim YT, Kang BJ: A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia. Human Psychopharmacology: Clinical and Experimental 19(4):265–269, 2004CrossRefGoogle Scholar
  25. 25.
    Haddad PM, Hellewell JSE, Wieck A: Antipsychotic induced hyperprolactinaemia: A series of illustrative case reports. Journal of Psychopharmacology 15(4):293–295, 2001PubMedCrossRefGoogle Scholar
  26. 26.
    Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al.: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. American Journal of Psychiatry 164(3):415–427, 2007Google Scholar
  27. 27.
    Ciudad A, Alvarez E, Bousono M, Olivares JM, Gomez JC: Safety and tolerability of olanzapine versus risperidone: A one-year randomized study in outpatients with schizophrenia with prominent negative symptoms. Actas Españolas de Psiquiatría 35(2):105–114, 2007PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Katarina Melo Chaves
    • 8
  • Antoni Serrano-Blanco
    • 7
  • Susana Barbosa Ribeiro
    • 8
  • Luiz Alberto Lira Soares
    • 5
    • 6
  • Gerlane Coelho Bernardo Guerra
    • 3
  • Maria do Socorro Costa Feitosa Alves
    • 4
  • Raimundo Fernandes de Araújo Júnior
    • 1
  • Vanessa de Paula Soares Rachetti
    • 2
  • Antônio Filgueira Júnior
    • 9
  • Aurigena Antunes de Araújo
    • 3
  1. 1.Department of Morphology/Postgraduate Program in Morphological SciencesFederal University of Rio Grande do NorteNatalBrazil
  2. 2.Department of Biophysics and PharmacologyFederal University of Rio Grande do NorteNatalBrazil
  3. 3.Department of Biophysics and PharmacologyPostgraduate Program in Pharmaceutical Sciences of Federal University of Rio Grande do NorteNatalBrazil
  4. 4.Department of Dentistry/Postgraduate Program in Collective HealthFederal University of Rio Grande do NorteNatalBrazil
  5. 5.Postgraduate Program in Pharmaceutical SciencesFederal University of Rio Grande do NorteNatalBrazil
  6. 6.Postgraduate Program in Pharmaceutical SciencesFederal University of PernambucoRecifeBrazil
  7. 7.Parc Sanitari Sant Joan de DéuSant Boi de LlobregatBarcelonaSpain
  8. 8.Pharmaceutical ScienceFederal University of Rio Grande do NorteNatalBrazil
  9. 9.Hospital da Polícia Militar of Rio Grande do NorteNatalBrazil

Personalised recommendations